- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.04. | Degroof Petercam Initiates Coverage of Oncodesign Precision Medicine | 211 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen | |
| 17.04. | Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101 | 220 | Business Wire | DEMOCRITE Project: Demonstrating the efficiency of OPM-101 by targeting RIPK2 in Inflammatory Bowel Disease
Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic:... ► Artikel lesen | |
| 26.03. | Oncodesign Precision Medicine: OPM Publishes Its Annual Results for 2023 and Provides an Update on Its Clinical Developments | 257 | Business Wire | R&D investment up 27% to €8.8 M, mainly linked to the clinical development of OPM-101 and the start of a preclinical program in oncology OPM-102 Cash position of €10 M on December the... ► Artikel lesen | |
| 29.02. | Oncodesign Precision Medicine Obtains Deep Tech Development Funding for Its ANIMUS Program | 351 | Business Wire | ANIMUS program: development of proprietary methods using AI to optimize molecules derived from our Nanocyclix® technology, for faster selection of drug candidates
Regulatory News:
Oncodesign... ► Artikel lesen | |
| 25.01. | Oncodesign Precision Medicine receives ERDF fund totalling €2.1 M for its COMETE program | 378 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM) (Paris:ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant... ► Artikel lesen | |
| 12.12.23 | TP ICAP Midcap Initiates Coverage of Oncodesign Precision Medicine With a "Buy" Recommendation | 388 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM) (Paris:ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant... ► Artikel lesen | |
| 05.10.23 | Oncodesign Precision Medicine: Oncodesign Precision Medicine Announces a 6 Million Euros Bank Financing from Caisse d'Épargne Bourgogne Franche Comté, Crédit Agricole de Champagne Bourgogne and Société Générale | 525 | Business Wire | This non-dilutive financing enables OPM to continue the clinical development of OPM-101 and to support the development of its products portfolio and technologies
This unique and strategic... ► Artikel lesen | |
| 02.10.23 | Oncodesign Precision Medicine: OPM Announces Positive Interim Results of Its Phase 1 Study Evaluating OPM-101 in Healthy Volunteers | 380 | Business Wire | Completion of the single-dose administration (SDA) part of the Phase 1 healthy volunteers study of OPM-101 and transition to the multiple-dose escalation administration (MDA) A new mechanism... ► Artikel lesen | |
| 19.09.23 | Oncodesign Precision Medicine: OPM Announces Its Results for the First Half of 2023 | 517 | Business Wire | One Year After Its Creation, OPM Continues to Successfully Complete the Clinical Development of Its Drug Candidate OPM 101 and Its Technological Platforms Cash position of 9.5M to ensure... ► Artikel lesen | |
| 30.05.23 | Oncodesign Precision Medicine: Report of the annual General Meeting of 30 May 2023 | 500 | Business Wire | Nomination of Florence Dupré as a member of the Board of Directors
Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,585 | +1,29 % | Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group | © Foto: Porsche AG NewsroomGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:55... ► Artikel lesen | |
| EVOTEC | 9,895 | +1,59 % | Neuer CEO, alte Probleme: Wie geht es weiter für Evotec | Die Aktie von Evotec erlebte einen dramatischen Kurseinbruch um 35 Prozent, nachdem das Unternehmen enttäuschende Nachrichten über seine Profitabilität verkündet hatte. Trotz Bemühungen, nach einem... ► Artikel lesen | |
| MORPHOSYS | 66,10 | -0,15 % | Novartis-Übernahme läuft: Verlust verzehnfacht: Morphosys muss "Karten auf den Tisch legen" | © Foto: Sven Hoppe/dpaDie geplante Übernahme durch Novartis sorgt für hohe Kosten und lassen die Verluste bei Morphosys explodieren. Für Unruhe sorgt ein Fachartikel zu Sicherheit des Krebsmedikaments... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 43,820 | -6,45 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 4,100 | +167,62 % | CytomX-Aktie +259%: Top-Empfehlung dreht völlig durch! | Mit der Aktie des Biotech-Unternehmens CytomX Therapeutics (WKN: A14158) knallt einer unserer Top-Tipps am Mittwoch in der Spitze um +259% von 1,63 US$ bis auf 5,85 US$ in die Höhe - bei absoluten Rekordumsätzen... ► Artikel lesen | |
| BIONTECH | 85,65 | +2,39 % | Evotec, Vidac Pharma, BioNTech - das Milliardenrennen um die Krebstherapie | Die Onkologie steht an der Schwelle zu einer goldenen Ära. Getrieben von einer Zunahme der Krebserkrankungen und beeindruckenden wissenschaftlichen Fortschritten, darunter Gen- und Immuntherapien, eröffnet... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,470 | +1,56 % | Recursion Pharmaceuticals: Recursion to Participate in Upcoming Investor Conferences | ||
| MODERNA | 111,16 | +7,57 % | Verhaltene Impfstoff-Nachfrage: BioNTech-Konkurrent Moderna: Umsatz bricht um 91 Prozent ein | © Foto: picture alliance / Geisler-Fotopress | Christoph Hardt/Geisler-FotopresTrotz erneut gesunkener Erlöse hat Biotech-Unternehmen Moderna die Erwartungen der Analysten übertreffen können. Dennoch... ► Artikel lesen | |
| CABALETTA BIO | 12,425 | +0,12 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| JANUX THERAPEUTICS | 57,92 | -0,46 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| MERRIMACK PHARMACEUTICALS | 15,010 | +0,23 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| BEAM THERAPEUTICS | 22,400 | +3,04 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,780 | -0,19 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 8,590 | -2,72 % | Arcutis Biotherapeutics, Inc.: Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 | ||
| ARCELLX | 53,23 | +2,05 % | Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights | -- Expanded strategic partnership with Kite --
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen |
ONCODESIGN PRECISION MEDICINE SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,36 % bei einem Aktienkurs von 1,410 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
